Current neoadjuvant treatment options for HER2-positive breast cancer

References

• MakhoulIKiwanENeoadjuvant systemic treatment of breast cancerJ Surg Oncol201110334835721337570
   PubMed Web of Science ®Google Scholar
• KaufmannMvon MinckwitzGBearHDRecommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: New perspectives 2006Ann Oncol2007181927193417998286
   PubMed Web of Science ®Google Scholar
• BuzdarAUPreoperative chemotherapy treatment of breast cancer – a reviewCancer20071102394240717941030
   PubMed Web of Science ®Google Scholar
• SpechtJGralowJRNeoadjuvant chemotherapy for locally advanced breast cancerSemin Radiat Oncol20091922222819732686
   PubMed Web of Science ®Google Scholar
• KimROsakiATogeTCurrent and future roles of neoadjuvant chemotherapy in operable breast cancerClin Breast Cancer2005622323216137432
   PubMedGoogle Scholar
• KurosumiMSignificance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancerBreast Cancer20061325425916929118
   PubMedGoogle Scholar
• MillerWRClinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancerJ Steroid Biochem Mol Biol201011827327619837160
   PubMed Web of Science ®Google Scholar
• MathewJAsgeirssonKSCheungKLChanSDahdaARobertsonJFNeoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directionsEur J Surg Oncol2009311312218502088
   PubMed Web of Science ®Google Scholar
• WolmarkNWangJMamounasEPreoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18J Natl Cancer Inst Monogr2001309610211773300
   PubMedGoogle Scholar
• RastogiPAndersonSJBearHDPreoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27J Clin Oncol20082677878518258986
   PubMed Web of Science ®Google Scholar
• Van der HageJAvan de VeldeCJJulienJPPreoperative chemotherapy in primary operable breast cancer: Results from the European Organization for Research and Treatment of Cancer trial 10902J Clin Oncol2001194224423711709566
   PubMed Web of Science ®Google Scholar
• BearHDAndersonSSmithRESequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27J Clin Oncol2006242019202716606972
   PubMed Web of Science ®Google Scholar
• SmithIHeysSHutcheonANeoadjuvant chemotherapy in breast cancer: Significantly enhanced response with docetaxelJ Clin Oncol2002201456146611896092
   PubMed Web of Science ®Google Scholar
• BargmannCIHungMCWeinbergRAThe neu oncogene encodes an epidermal growth factor receptor-related proteinNature19863192262303945311
   PubMed Web of Science ®Google Scholar
• RossJSFletcherJALinetteGPThe Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapyOncologist2003830732512897328
   PubMed Web of Science ®Google Scholar
• SahinAABiologic and clinical significance of HER-2/neu (cerbB-2) in breast cancerAdv Anat Pathol2000715816610809222
   PubMed Web of Science ®Google Scholar
• TsudaHHPrognostic and predictive value of c-erbB-2 (HER-2/neu) gene amplification in human breast cancerBreast Cancer20018384411180764
   PubMedGoogle Scholar
• PegramMDLiptonAHayesDFPhase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatmentJ Clin Oncol199816265926719704716
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med200134478379211248153
   PubMed Web of Science ®Google Scholar
• BursteinHJHarrisLNMarcomPKTrastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithmJ Clin Oncol2003212889289512885806
   PubMed Web of Science ®Google Scholar
• BartschRWenzelCGampenriederSPTrastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancerCancer Chemother Pharmacol20086290391018256835
   PubMed Web of Science ®Google Scholar
• BartschRWenzelCAltorjaiGCapecitabine and trastuzumab in heavily pretreated metastatic breast cancerJ Clin Oncol2007253853385817679724
   PubMed Web of Science ®Google Scholar
• BartschRWenzelCAltorjaiGResults from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancerBreast Cancer Res Treat200710237538117028979
   PubMed Web of Science ®Google Scholar
• ChanAMartinMUntchMVinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: An international phase II trialBr J Cancer20069578879316969343
   PubMed Web of Science ®Google Scholar
• AnderssonMLidbrinkEBjerreKPhase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2–positive breast cancer: The HER-NATA studyJ Clin Oncol20112926427121149659
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med20053531659167216236737
   PubMed Web of Science ®Google Scholar
• SmithIProcterMGelberRD2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trialLancet2007369293617208639
   PubMed Web of Science ®Google Scholar
• JoensuuHBonoPKatajaVFluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer TrialJ Clin Oncol2009275685569219884557
   PubMed Web of Science ®Google Scholar
• SpielmannMRochéHDelozierTTrastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trialJ Clin Oncol2009276129613419917839
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNEResults of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER-2 positive adjuvant breast cancer trialAbstr 80 presented at the 32nd Annual San Antonio Breast Cancer SymposiumSan Antonio, TXDecember 9–13, 2009
   Google Scholar
• SlamonDEiermannWRobertNPhase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 StudyAbstr 62 presented at the 32nd Annual San Antonio Breast Cancer SymposiumSan Antonio, TXDecember 9–13, 2009
   Google Scholar
• BuzdarAUIbrahimNKFrancisDSignificantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerJ Clin Oncol2005233676368515738535
   PubMed Web of Science ®Google Scholar
• BuzdarAUValeroVIbrahimNKNeoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimenClin Cancer Res20071322823317200359
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohortLancet201037537738420113825
   PubMed Web of Science ®Google Scholar
• UntchMRezaiMLoiblSNeoadjuvant treatment with trastuzumab in HER2-positive breast cancer: Results from the GeparQuattro studyJ Clin Oncol2010282024203120308670
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol2001212713711252954
   PubMed Web of Science ®Google Scholar
• RowinskyEKSignal events: Cell signal transduction and its inhibition in cancerOncologist2003851714671224
   PubMed Web of Science ®Google Scholar
• HsiehACMoasserMMTargeting HER proteins in cancer therapy and the role of the non-target HER3Br J Cancer20079745345717667926
   PubMed Web of Science ®Google Scholar
• BaselgaJSwainSMNovel anticancer targets: Revisiting HER2 and discovering HER3Nat Rev Cancer2009946347519536107
   PubMed Web of Science ®Google Scholar
• Graus-PortaDBeerliRRDalyJMHynesNEErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalingEMBO J199716164716559130710
   PubMed Web of Science ®Google Scholar
• Lee-HoeflichSTCrockerLYaoEA central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapyCancer Res2008685878588718632642
   PubMed Web of Science ®Google Scholar
• FranklinMCCareyKDVajdosFFLeahyDJde VosAMSliwkowskiMXInsights into ErbB signalling from the structure of the ErbB2-pertuzumab complexCancer Cell2004531732815093539
   PubMed Web of Science ®Google Scholar
• HughesJBBergerCRødlandMSHasmannMStangEMadshusIHPertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerizationMol Cancer Ther200981885189219584234
   PubMed Web of Science ®Google Scholar
• CitriASkariaKBYardenYThe deaf and the dumb: The biology of ErbB-2 and ErbB-3Exp Cell Res2003284546512648465
   PubMed Web of Science ®Google Scholar
• XiaWMullinRJKeithBRAnti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene2002216255626312214266
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med20063552733274317192538
   PubMed Web of Science ®Google Scholar
• BaselgaJBradburyIEidtmannHFirst results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER 2-positive primary breast cancerAbstr S3-3 presented at the 32nd Annual San Antonio Breast Cancer SymposiumSan Antonio, TXDecember 9–13, 2009
   Google Scholar
• ClinicalTrials.govA randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer Available from: http://clinicaltrials.gov/ct2/show/NCT00490139. Accessed June 1st, 2011.
   Google Scholar
• GianniLPienkowskiTImYHNeoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ‘Neosphere’Abstr S3-2 presented at the 32nd Annual San Antonio Breast Cancer SymposiumSan Antonio, TXDecember 9–13, 2009
   Google Scholar
• ThomasEHolmesFASmithTLThe use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: Long-term results from a prospective randomized trialJ Clin Oncol2004222294230215197190
   PubMed Web of Science ®Google Scholar
• HennessyBTHortobagyiGNRouzierROutcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapyJ Clin Oncol2005239304931116361629
   PubMed Web of Science ®Google Scholar
• UntchMFaschingPAKonecnyGEPathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy: Three year median follow-up data of the TECHNO TrialAbstr P1-11-03 presented at the 32nd Annual San Antonio Breast Cancer SymposiumSan Antonio, TXDecember 9–13, 2009
   Google Scholar
• BriaECupponeFFornierMCardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: The dark side of the moon? A meta-analysis of the randomized trialsBreast Cancer Res Treat200810923117638068
   PubMed Web of Science ®Google Scholar
• ChienAJRugoHSThe cardiac safety of trastuzumab in the treatment of breast cancerExpert Opin Drug Saf2010933534620175700
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govA randomized Phase III trial of neoadjuvant therapy for patients with palpable and operable HER2-positive breast cancer comparing the combination of trastuzumab plus lapatinib to trastuzumab and to lapatinib administered with weekly paclitaxel following ac accompanied by correlative science studies to identify predictors of pathologic complete response Available from: http://clinicaltrials.gov/ct2/show/NCT00180973. Accessed June 1st, 2011.
   Google Scholar
• LadjemiMZJacotWChardèsTNew prospects for breast cancer therapyCancer Immunol Immunother2010591295131220532501
   PubMed Web of Science ®Google Scholar